Xencor Names New VP

Monrovia, California-based biopharmaceuticals developer Xencor announced today that it has named Raphael Clynes, M.D., Ph.D., as its new Vice President of Translational Biology. Clynes was most recently Group Medical and Scientific Director of Immunology-oncology at Bristol-Myers Squib, was co-founder of Vixen Pharmaceuticals, and was an associate professor at Columbia University. Xencor said Dr. Cylnes will study the biological mechanisms of its antibody drug candidates, particularly in immuno-oncology.